Stereotactic ablative body radiation therapy

RADIATION2 trials

Sponsors

University of Texas Southwestern Medical Center, Baptist Health South Florida

Conditions

Metastatic CarcinomaMetastatic Clear Cell Renal Cell Carcinoma

Phase 2

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

CompletedNCT01896271

University of Texas Southwestern Medical CenterMetastatic Clear Cell Renal Cell Carcinoma

Start: 2013-10-02End: 2021-04-20Updated: 2021-08-23

Unknown Phase

Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction

CompletedNCT04939246

Baptist Health South FloridaMetastatic Carcinoma

Start: 2021-06-18End: 2024-07-17Updated: 2025-07-17

Related Papers

Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.

2025-03-282 citations

Discordance of patient- and physician-reported toxicities in two prospective trials of stereotactic body radiotherapy (SBRT) for localized prostate cancer.

Journal of Clinical Oncology2022-02-16

Phase II trial of high-dose interleukin-2 (IL-2) and stereotactic radiation therapy (SABR) for metastatic clear cell renal cell carcinoma (ccRCC): Interim analysis.

Journal of Clinical Oncology2016-01-1011 citations